Osteogenesis imperfecta: diagnosis and treatment

Area of Science:

• Genetics and Molecular Biology
• Pediatric Endocrinology
• Orthopedics

Background:

• Osteogenesis imperfecta (OI) is a rare genetic disorder characterized by brittle bones.
• Mutations in COL1A1 and COL1A2 are the primary cause, but at least 17 other genes are implicated.
• OI affects bone fragility, leading to frequent fractures and skeletal deformities.

Purpose of the Study:

• To review current diagnostic approaches for osteogenesis imperfecta.
• To discuss recently identified genes associated with OI.
• To summarize management strategies for OI in pediatric and adult populations.

Main Methods:

• Literature review of diagnostic criteria for osteogenesis imperfecta.
• Analysis of genetic studies identifying novel genes in OI.
• Evaluation of current and emerging therapeutic interventions for OI.

Main Results:

• Over 17 additional genes beyond COL1A1/COL1A2 have been linked to OI phenotypes.
• Intravenous bisphosphonates are the standard treatment, effective for vertebral reshaping but less so for long bones.
• New therapeutic agents are under investigation for OI management.

Conclusions:

• Despite diagnostic and therapeutic advancements, further research into osteogenesis imperfecta is essential.
• Bisphosphonates reduce long-bone fractures but do not eliminate them.
• Novel antiresorptive and anabolic agents require further study for safety and efficacy, particularly in pediatric patients.